Augmentation of Nrf2-mediated responses to haemorrhagic brain injury is a potential therapeutic strategy, particularly because older populations with ICH may not exhibit a maximal Nrf2-mediated transcriptional response. The gene discussed is NFE2L2; the disease is brain injury.